Trends in Allogeneic Stem Cell Transplantation for Good Risk Acute Myelogenous Leukemia in First Complete Remission: A Longitudinal Study of> 15 Years from the …
Background: Favorable acute myelogenous leukemia (AML) includes AML with t (8: 21), inv
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …
(16), and those with NPM1 without FLT3-ITD without adverse cytogenetics (ELN 2022). The …
[HTML][HTML] Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Complete Remission: A Longitudinal Study of> 15 Years from the …
Background Allogeneic transplantation (HSCT) is usually not indicated in favorable risk AML
at CR1due to transplant-related mortality. However, in recent years, HSCTs are with …
at CR1due to transplant-related mortality. However, in recent years, HSCTs are with …
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of> 15 years from the ALWP of the EBMT
We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1
over 3 time periods. 1850 patients were included, 2005 to 2009-222, 2010 to 2014-392, and …
over 3 time periods. 1850 patients were included, 2005 to 2009-222, 2010 to 2014-392, and …
[HTML][HTML] Allogeneic stem cell transplantation improves survival in patients with FLT3-ITD-negative and NPM1-wild type intermediate risk (ELN) acute myeloid leukemia
K Heidrich, C Thiede, K Schäfer-Eckart, N Schmitz… - Blood, 2016 - Elsevier
Background: So called triple-negative acute myeloid leukemias (AML) form a
heterogeneous subgroup of intermediate-risk AML according to ELN criteria. Molecularly …
heterogeneous subgroup of intermediate-risk AML according to ELN criteria. Molecularly …
[HTML][HTML] Allogeneic hematopoietic stem-cell transplantation (HSCT) in first complete remission is superior compared to chemotherapy/autologous HSCT in patients …
Prognosis of acute myeloid leukemia (AML) is mainly determined by presenting cyto-and
molecular genetics, as systematized in the recent European LeukemiaNet (ELN) risk …
molecular genetics, as systematized in the recent European LeukemiaNet (ELN) risk …
[HTML][HTML] Low risk of chronic graft-versus-host disease and relapse associated with T cell–depleted peripheral blood stem cell transplantation for acute myelogenous …
Graft-versus-host disease (GVHD) is most effectively prevented by ex vivo T cell depletion
(TCD) of the allograft, but its role in the treatment of patients undergoing allogeneic …
(TCD) of the allograft, but its role in the treatment of patients undergoing allogeneic …
[HTML][HTML] Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal …
In patients with acute myeloid leukemia (AML) of intermediate-risk (IR) in first remission
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
(CR1) with no measurable residual disease (MRD negative), the choice of the best …
Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
Purpose: We evaluated outcomes of unrelated transplantation for primary
refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according …
refractory/relapsed (ref/rel) acute myeloid leukemia (AML), comparing two cohorts according …
Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation
O Beyar-Katz, N Lavi, S Ringelstein-Harlev… - Leukemia & …, 2019 - Taylor & Francis
Autologous stem cell transplantation (ASCT), intensifying anti-leukemic effects without
significant treatment-related mortality (TRM), is particularly appealing in AML with favorable …
significant treatment-related mortality (TRM), is particularly appealing in AML with favorable …
[HTML][HTML] Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without …
G Labouré, S Dulucq, M Labopin, R Tabrizi… - Biology of Blood and …, 2012 - Elsevier
To investigate the role of reduced-intensity allogeneic (RIC-allo) stem cell transplant (SCT)
as postremission therapy in adult intermediate-risk patients with acute myelogenous …
as postremission therapy in adult intermediate-risk patients with acute myelogenous …